Latest News
Lilly declares Q2 2026 dividend
5 May 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that its board of directors has approved a dividend of USD1.73 per share on its outstanding common stock for the second quarter of 2026.This amount is unchang...
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
5 May 2026 - US life sciences company Lunai Bioworks Inc (NASDAQ:LNAI) announced on Monday the completion of a USD20m preferred equity issuance to acquire intellectual property assets from two counterparties, expanding the company's central nerv...
Neurocrine Biosciences survey shows significant burden of tardive dyskinesia on employment and education
5 May 2026 - US biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Monday announced the release of findings from a new survey revealing the significant impact of tardive dyskinesia (TD) on people's ability to work, go to schoo...
Atossa Therapeutics' (Z)-endoxifen receives FDA Rare Pediatric Disease designation for McCune-Albright Syndrome
5 May 2026 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq:ATOS) announced on Monday that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for the treatment of ...
Photocure study supports cost-effectiveness of blue light cystoscopy
4 May 2026 - Norwegian bladder cancer company Photocure ASA (OSE: PHO) announced on Monday the publication of a new health economic methodology in The Journal of Medical Economics demonstrating that blue light cystoscopy is cost-effective compared wi...